Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Glen J., Tibes, Raoul, Blaydorn, Lisa, Jameson, Gayle, Downhour, Molly, White, Erica, Caro, Ivor, Von Hoff, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211514/
https://www.ncbi.nlm.nih.gov/pubmed/25386306
http://dx.doi.org/10.4081/dr.2011.e55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211514/
https://www.ncbi.nlm.nih.gov/pubmed/25386306
http://dx.doi.org/10.4081/dr.2011.e55

Ejemplares similares